Holen Sie sich die Stockscreener-App
26.96
2.27%
0.79
Schlusskurs vom Vortag:
$26.17
Offen:
$26.18
24-Stunden-Volumen:
62,901
Relative Volume:
0.26
Marktkapitalisierung:
$1.83B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-48.26M
KGV:
-34.13
EPS:
-0.7899
Netto-Cashflow:
$-45.04M
1W Leistung:
-0.43%
1M Leistung:
+24.90%
6M Leistung:
+49.11%
1J Leistung:
+78.37%
1-Tages-Spanne:
$25.47
$27.10
1-Wochen-Bereich:
$25.47
$27.30
52-Wochen-Spanne:
$11.32
$28.96
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
26.71 | 1.85B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
524.08 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.73 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.94 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.12 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.00 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Needham | Buy |
| 2025-06-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2025-03-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-02-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-08-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-16 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Gh Research Plc Aktie (GHRS) Neueste Nachrichten
Price to sales forward of GH Research PLC – NASDAQ:GHRS - TradingView
GHRSGH Research PLC Options - Finviz
GH RESEARCH PLC (GHRS) Stock Chart - ChartMill
GH Research Plc Actuals & Estimates (FWB:1KA) - TradingView
Pre-Market Movement | GH Research Shares Surge to 52-Week High - 富途牛牛
GHRS Forecast — Price Target — Prediction for 2027 - TradingView
GHRS Stock Price and Chart — NASDAQ:GHRS - TradingView
(GHRS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
GH Research PLC stock hits 52-week high at 25.98 USD - Investing.com
GH Research Shareholders Approve Director Slate and 2026 Auditor at June AGM - TipRanks
GH Research PLC (GHRS) re-elects directors and ratifies PwC Ireland at AGM - Stock Titan
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year - Sahm
GH Research Plc Actuals & Estimates (MUN:1KA) - TradingView
These analysts revise their forecasts on GH Research after Q1 results - MSN
GH Research PLC (GHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GH Research PLC (GHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
What GH Research (GHRS)'s Phase 2a Postpartum Depression Breakthrough Means For Shareholders - simplywall.st
GH Research PLC (GHRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
GH Research PLC (GHRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GH Research PLC (GHRS) Institutional Confidence - TradingKey
GH Research PLC (GHRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GH Research PLC (GHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GH Research PLC (GHRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GH Research PLC (GHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
(GHRS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
GH Research (GHRS) Stock Valuation After Positive Phase 2a Mebufotenin Data In Postpartum Depression - Sahm
GH Research (GHRS) Bounces 2.23% as Shares Test Key Resistance at $22.18Exhaustion Gap - newsline.com
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss, Stock Rises on Pipeline Progress - dars.gov.et
GHRS Q1 2026 Earnings: Clinical-Stage Biotech Reports Narrower-Than-Expected Operating Loss Amid Pipeline ProgressEarnings Power Value - newsline.com
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy? - simplywall.st
GH Research PLC (GHRS) Gains Ground After Testing Support, Resistance in FocusAscending Triangle - newsline.com
GH Research Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical DevelopmentReturn On Assets - newsline.com
GHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
H.C. Wainwright Maintains Buy Rating on GH Research (GHRS) - Insider Monkey
GH Research earnings ahead: Can cash sustain Phase 3 ambitions? - Investing.com
5 Stocks That Have the Potential to Rise 1000% - Insider Monkey
(GHRS) Risk Channels and Responsive Allocation - Stock Traders Daily
GH Research Publishes Positive Phase 2a Postpartum Depression Data and Secures CINP 2026 Slots for GH001 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2 GH001 results in postpartum and treatment-resistant depression - Stock Titan
GH Research publishes phase 2a postpartum depression results By Investing.com - Investing.com Australia
GH Research publishes phase 2a postpartum depression results - Investing.com
GH Research Announces Publication of Phase 2a Postpartum Depression Results - Yahoo Finance UK
GHRS Q1 2026 Earnings: Miss on EPS as Clinical-Stage Biotech Deepens R&D InvestmentFinancial Health Score - newsline.com
Psychedelic drug stocks are surging after Trump's order to fast-track development for medical use - AOL.com
GH Research (GHRS) Surges Over 7%: Testing Key Resistance at $25.19Short Term Trading Ideas - dars.gov.et
GH Research (GHRS) Surges 7.19% as Breakout Above $25.19 Resistance Becomes Key TestOvernight Profile - The Legal Advocate
Certain Options of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
62,029,395 Common Stock of GH Research PLC are subject to a Lock-Up Agreement Ending on 30-MAY-2026. - marketscreener.com
GH Research (GHRS) Jumps 3.35% as Shares Approach Key Resistance at $24.0Insider Selling Alerts - The Legal Advocate
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
GH Research Stock Moves as Market Eyes Data in Holiday Week - Bez Kabli
Finanzdaten der Gh Research Plc-Aktie (GHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.60%
1.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):